The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), with a price target ...

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

BioNTech SE (“BioNTech”) confirmed the completion of its acquisition of biotechnology company Biotheus for an upfront payment ...

After a major increase in deaths from COVID-19 in December, Carver County Public Health Director Richard Scott says numbers are dropping as the new year continues. Half of the county’s death ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...

BioNTech's financial position is robust, with approximately $18 billion in cash following the Biotheus acquisition. According to InvestingPro data, the company maintains an impressive current ...